Kenneth Lock
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Kenneth Lock
Arcutis Biotherapeutics, Inc. reported in an 8-K filed May 24, 2023 that Kenneth Lock resigned as Senior Vice President and Chief Commercial Officer, effective June 2, 2023. The proxy statement of Arcutis Biotherapeutics, Inc. reports total compensation of $1,270,018 for Kenneth Lock in fiscal 2022, including a base salary of $392,500. Disclosed compensation is on record for 2 fiscal years.
“On May 22, 2023, Kenneth Lock notified Arcutis Biotherapeutics, Inc. (the "Company") of his decision to resign as Senior Vice President and Chief Commercial Officer of the Company, effective as of June 2, 2023, to attend to personal matters.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Arcutis Biotherapeutics, Inc. (ARQT)
Proxy statement
Start not stated–2023-06-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Arcutis Biotherapeutics, Inc. (ARQT) | — | $392,500 | $1,270,018 |
| 2020 | Arcutis Biotherapeutics, Inc. (ARQT) | — | $335,000 | $1,267,692 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.